Vitamin D Research

back to research menu

Diabetes

• Association between 25‑hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney dysfunction. Nephrol Dial Transplant. Epub 2007.09.17.
• Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes. Diabetes. 2007;56:2616–2621.
• CYP2R1 (vitamin D 25‑hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev. Epub 2007.07.02.
• Correlation between vitamin D(3) deficiency and insulin resistance in pregnancy. Diabetes Metab Res Rev. Epub 2007.07.02.
• What is new in vitamin D: 2006–2007. Curr Opin Rheumatol. 2007 Jul;19(4):383–8.
• The Role of Vitamin D and Calcium in type 2 diabetes. A systematic Review and Meta‑Analysis. J Clin Endocrinol Metab. 2007 Jun;92(6):2017–29. Review.
• Vitamin D and outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens. 2007 Mar;16(2):77–82.
• The Effects of Calcium and Vitamin D Supplementation on Blood Glucose and Markers of Inflammation in Non‑diabetic Adults. Diabetes Care. Epub 2007.02.02.
• 25‑Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int. 2007 Jan;71(2):134–9.
• Lower levels of plasma 25‑hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia. 2006 Dec;49(12):2847–52.
• Serum 25‑hydroxyvitamin D3 concentrations and carotid artery intima‑media thickness among type 2 diabetic patients. Clin Endocrinol (Oxf). 2006 Nov;65(5):593–597.
• Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol. 2006 Oct;21(10):1434–9.
• Renal function and 25‑hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients. Nephrol Dial Transplant. 2006 Sep;21(9):2621–4.
• Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol. 2006 Sep;92(1):39–48. Review.
• Vitamin D physiology. Prog Biophys Mol Biol. 2006 Sep;92(1):4–8. Review.
• Vitamin D deficiency: A global perspective. Arq Bras Endocrinol Metabol. 2006 Aug;50(4):640–6.
• A prospective study of dairy intake and the risk of type 2 diabetes in women. Diabetes Care. 2006 Jul;29(7):1579–84.
• Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle‑aged and older U.S. women. Diabetes Care. 2005 Dec;28(12):2926–32.
• Vitamin D endocrine system and the genetic susceptibility to diabetes, obesity and vascular disease. A review of evidence. Diabetes Metab. 2005 Sep;31(4 Pt 1):318–25. Review.
• Heterogeneity of vitamin D receptor gene association with celiac disease and type 1 diabetes mellitus. Autoimmunity. 2005 Sep;38(6):439–44.
• The role of vitamin D in protecting type 1 diabetes mellitus. Diabetes Metab Res Rev. 2005 Jul–Aug;21(4):338–46. Review.
• Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev. 2005 Jun;10(2):94–111. Review.
• Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol. 2005 May;20(5):622–30.
• Vitamin D and the elderly. Clin Endocrinol (Oxf). 2005 Mar;62(3):265–81. Review.
• Are low plasma levels of 25‑(OH)vitamin D a major risk factor for hyperparathyroidism independent of calcitriol in renal transplant patients? J Nephrol. 2005 Jan–Feb;18(1):96–101.
• Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study. Ren Fail. 2005;27(2):205–12.
• Oral administration of 1,25‑dihydroxyvitamin D3 completely protects NOD mice from insulin‑dependent diabetes mellitus. Arch Biochem Biophys. 2003 Sep 1;417(1):77–80.
• The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract. 2003 May;57(4):258–61.
• Vitamin D and autoimmune diabetes. J Cell Biochem. 2003 Feb 1;88(2):216–22. Review.
• Ultraviolet radiation and health: friend and foe. Med J Aust. 2002 Dec 2–16;177(11–12):594–8.
• The role of vitamin D in mild to moderate chronic kidney disease. Trends Endocrinol Metab. 2002 Jul;13(5):189–94. Review.
• Can vitamin D supplementation in infancy prevent type 1 diabetes? Nutr Rev. 2002 Apr;60(4):118–21. Review.
• Intake of vitamin D and risk of type 1 diabetes: a birth‑cohort study. Lancet. 2001 Nov 3;358(9292):1500–3.
• The effect of long‑term intravenous calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol. 1991 Nov;2(5):1014–20.
• Effect of calcitriol treatment and withdrawal on hyperparathyroidism in haemodialysis patients with hypocalcaemia. Nephrol Dial Transplant. 2001 May;16(5):1009–16.
• Vitamin D and estrogen receptor gene polymorphisms in type 2 diabetes mellitus and in android type obesity. Eur J Endocrinol. 2001 Apr;144(4):385–9.
• Use of cod liver oil during pregnancy associated with lower risk of Type I diabetes in the offspring. Diabetologia. 2000 Sep;43(9):1093–8.
• Effect of calcitriol and age on recovery from hypocalcemia in hemodialysis patients. Am J Kidney Dis. 1999 Sep;34(3):456–63.
• Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Kidney Int. 1999 Jul;56(1):306–17.
• Vitamin D supplement in early childhood and risk for Type I (insulin‑dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group. Diabetologia. 1999 Jan;42(1):51–4.
• Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19‑nor‑1,25‑dihydroxyvitamin D2. Am J Kidney Dis. 1998 Oct;32(2 Suppl 2):S48–54.
• 19‑Nor‑1‑alpha‑25‑dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998 Aug;9(8):1427–32.
• A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients. Miner Electrolyte Metab. 1997;23(1):13–8.
• "Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study. Nephron. 1997;77(3):267–72.
• Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol. 1996 Mar;7(3):488–96.
• Different effects of calcitriol and parathyroidectomy on the PTH‑calcium curve in dialysis patients with severe hyperparathyroidism. Nephrol Dial Transplant. 1996 Jan;11(1):81–7.
• Serum 25‑hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract. 1995 Mar;27(3):181–8.
• Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25‑dihydroxycholecalciferol. Intern Med. 1993 Sep;32(9):695–701.
• Secondary hyperparathyroidism in elderly people: combined effect of renal insufficiency and vitamin D deficiency. Am J Clin Nutr. 1993 Aug;58(2):187–91.
• Determinants of intact parathyroid hormone and free 1,25‑dihydroxyvitamin D levels in mild and moderate renal failure. Nephron. 1992;61(4):422–7.
• Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism. Nephrol Dial Transplant. 1992;7(8):822–8.
• The 'oral 1,25‑dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism. Nephron. 1991;57(1):23–8.
• Bone mineral content, 25‑hydroxycalciferol and zinc serum levels in insulin‑dependent (type I) diabetic patients. Arch Invest Med (Mex). 1990 Apr–Jun;21(2):195–9.
• Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int. 1989 Dec;36(6):1093–8.
• Hyperparathyroidism and 1,25‑dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab. 1988 Nov;67(5):876–81.
• Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Diabetologia. 1986 Mar;29(3):142–5.
• Serum phosphate, parathyroid hormone and vitamin D metabolites in patients with chronic renal failure: effect of aluminum hydroxide administration. Nephron. 1985;40(3):286–91.
• Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25‑dihydroxy‑cholecalciferol in uremic patients. J Clin Invest. 1984 Dec;74(6):2136–43.
• Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25‑hydroxyvitamin D3. J Clin Endocrinol Metab. 1984 Dec;59(6):1063–9.
• Effect of dietary phosphorus on circulating concentrations of 1,25‑dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest. 1984 Jun;73(6):1580–9.

back to research menu